EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective

Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi

Clinical and Molecular Hepatology · 01.04.2023 · 29 (2) · 242-251

DOI: 10.3350/cmh.2023.0102 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2023. Verfasst von Hironori Koga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Eisai Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various issues have emerged in clinical practice. First, there is no established biomarker that can predict response to systemic therapy. Second, there is no established treatment regimen after primary systemic therapy, including combined immunotherapy. Third, there is no established treatment regimen for intermediate-stage HCC. These points make the current guidelines ambiguous. In this review, we present the Japanese guidelines for the diagnosis and treatment of HCC based on the latest evidence; introduce various efforts mainly in Japanese real-life practice to update these guidelines; and present our perspectives on future guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsHumansTreatment Outcome

Stichwörter der Autor:innen

BCLC stagingImmune checkpoint inhibitorsMolecular-targeted agentsRadiofrequency ablationTranscatheter arterial chemoembolization

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine.
  • Liver Cancer Research Division, Research Center for Innovative Cancer Therapy, Kurume University.

Förderung

  • Eisai Co. Ltd.

Zitieren

APA

Koga, H., Iwamoto, H., Suzuki, H., Shimose, S., Nakano, M., & Kawaguchi, T. (2023). Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective. Clinical and Molecular Hepatology, 29(2), 242-251. https://doi.org/10.3350/cmh.2023.0102

Vancouver

Koga H, Iwamoto H, Suzuki H, Shimose S, Nakano M, Kawaguchi T. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective. Clinical and Molecular Hepatology. 2023;29(2):242-251. doi:10.3350/cmh.2023.0102

BibTeX
@article{Koga2023,
  author = {Koga, Hironori and Iwamoto, Hideki and Suzuki, Hiroyuki and Shimose, Shigeo and Nakano, Masahito and Kawaguchi, Takumi},
  title = {Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective},
  journal = {Clinical and Molecular Hepatology},
  year = {2023},
  volume = {29},
  number = {2},
  pages = {242--251},
  doi = {10.3350/cmh.2023.0102}
}
Kostenlos starten →